Study wrapper · #639
[Optimization of the treatment of anxiety disorders with selank].
Editor's note
This is one of the relatively scarce human clinical reports on Selank, comparing phenazepam monotherapy (30 patients) with combined selank-plus-phenazepam treatment (40 patients) in anxiety-phobic, hypochondriac, and somatoform disorders, assessed with HDRS, CGI, Spielberger, UKU, and quality-of-life scales. The abstract does not describe randomization or blinding, so I classify it as a controlled clinical comparison rather than a formal RCT. Researchers reported that adding selank brought the anxiolytic response earlier and, importantly, reduced phenazepam's side-effect burden (attention/memory impairment, sedation, sexual and other disturbances) both during treatment and after benzodiazepine withdrawal, with a positive effect on quality of life. For Selank, this is meaningful human signal for an adjunctive, side-effect-sparing role, but from a small, likely open-label, single-center study in the Russian literature. Weigh it as suggestive, not definitive; evidence here is mixed given the design limits.
Plain-language abstract
This was a study in people with anxiety-related disorders, testing whether adding the peptide selank to a standard benzodiazepine tranquilizer (phenazepam) improved treatment. Thirty patients received phenazepam alone and forty received phenazepam plus selank. Doctors tracked symptoms and side effects using several standard rating scales, along with quality of life. In the group that also received selank, the anti-anxiety benefit appeared sooner, and the usual downsides of the tranquilizer — trouble with attention and memory, drowsiness, fatigue, sexual problems, emotional flatness, and dizziness on standing — were less troublesome, both during treatment and after stopping the tranquilizer. Patients on the combination also reported better quality of life. The report did not say patients were randomly assigned or that assessors were blinded, and the groups were small, so the findings are encouraging but not conclusive. It suggests selank may help reduce benzodiazepine side effects when used alongside them, an idea that needs confirmation in larger, rigorously controlled trials.